Add Indapamide to Perindopril
For a patient already on perindopril, you should add indapamide rather than amlodipine as the next antihypertensive agent. This recommendation is strongly supported by landmark trials demonstrating mortality and cardiovascular benefits with the perindopril/indapamide combination, particularly in high-risk populations.
Evidence Supporting Perindopril + Indapamide
The combination of perindopril and indapamide has robust outcome data from major cardiovascular trials:
ADVANCE Trial 1: In 11,140 patients with type 2 diabetes and cardiovascular risk factors, the perindopril/indapamide combination (compared to placebo added to existing therapy) demonstrated:
- Significant reduction in cardiovascular death (HR 0.82,95% CI 0.68-0.98)
- Reduction in total mortality (HR 0.86,95% CI 0.75-0.98)
- Additional BP reduction of 5.6/2.2 mmHg
- Low rates of serious adverse events and discontinuation
PROGRESS Trial 2: In patients with prior stroke or TIA, perindopril plus indapamide reduced stroke recurrence by 43% (RR 0.57,95% CI 0.46-0.70), while perindopril monotherapy showed no significant benefit 2.
The 2025 ADA Diabetes Care Standards specifically cite the ADVANCE trial's perindopril/indapamide combination as evidence for BP targets <130/80 mmHg in diabetic patients 3.
Why Not Amlodipine?
While amlodipine is an effective antihypertensive agent, the perindopril/amlodipine combination lacks the same level of mortality outcome data as perindopril/indapamide. The CAMELOT trial 4 studied amlodipine in CAD patients but focused on different endpoints and populations.
Key distinction: The perindopril/indapamide combination has demonstrated reductions in hard endpoints (cardiovascular death, total mortality) in multiple large trials, not just blood pressure reduction.
Current Guideline Support
The 2024 ESC Guidelines 5 recommend thiazide/thiazide-like diuretics (including indapamide) as first-line agents alongside ACE inhibitors. The preferred three-drug combination is explicitly stated as: "a RAS blocker with a dihydropyridine CCB and a thiazide/thiazide-like diuretic" 5.
The 2020 ISH Guidelines 6 similarly recommend adding a thiazide/thiazide-like diuretic as the third step after ACE inhibitor/ARB therapy.
The 2009 Canadian Hypertension Guidelines 1 specifically endorsed perindopril/indapamide combination therapy based on ADVANCE trial results, noting it was "associated with a significant reduction in cardiovascular death and total mortality" 1.
Practical Dosing
According to FDA labeling 7:
- Start indapamide 1.25 mg once daily in the morning
- May increase to 2.5 mg if needed after 4 weeks
- Maximum dose 5 mg daily (though doses >2.5 mg show minimal additional BP benefit with increased hypokalemia risk)
The ADVANCE trial used perindopril 4 mg + indapamide 2.5 mg (or 2.0 mg in Japan) 4.
Clinical Context Considerations
When amlodipine might be preferred instead:
- Patient has concurrent angina (amlodipine has specific anti-anginal benefits) 8
- Patient has significant electrolyte abnormalities or gout (contraindications to diuretics)
- Black patients may respond better to CCB + diuretic combinations initially 6
Monitoring requirements with indapamide:
- Check electrolytes (particularly potassium) within 2-4 weeks
- Monitor for hypokalemia, hyponatremia, hyperuricemia
- Assess renal function
The Three-Drug Combination
If BP remains uncontrolled on perindopril + indapamide, the next step would be adding amlodipine to create the triple combination of ACE inhibitor + thiazide-like diuretic + CCB 5. This triple combination (perindopril/indapamide/amlodipine) is available as a single-pill combination and has demonstrated excellent BP control (80-96% of patients achieving targets) with good tolerability 9, 10, 11, 12.
The evidence clearly favors adding indapamide to perindopril based on mortality outcomes, established guideline recommendations, and the complementary mechanisms of ACE inhibition plus thiazide-like diuretic therapy.